DUBLIN, March 3, 2022 /PRNewswire/ — The report “Cardiovascular and Soft Tissue Repair Patches Market by Application (Cardiac Repair, Vascular Repair, Pericardial Repair, Dural Repair, Soft Tissue Repair), by Raw Material, by Region and Segment Forecast, 2022-2030” has been added to from ResearchAndMarkets.com offer.

Global Cardiovascular and Soft Tissue Repair Patches Market Size is Expected to Reach $7.8 billion by 2030. The market is expected to grow at a CAGR of 8.4% from 2022 to 2030.

The rapid increase in the prevalence of congenital heart diseases, such as atrial septal defect (ASD) and ventricular septal defect is expected to drive the demand for patches. Additionally, increasing implementation of patches in medical procedures and growing sports injuries are expected to support the development and growth of the market over the coming years. According to studies, ASD is the second most common type of congenital heart disease and the incidence rate in the world population is 56 per 100,000 live births.

One of the major driving forces of the market is the rapid increase in the prevalence of cardiovascular diseases. Changing lifestyles, rising levels of obesity, adoption of unhealthy lifestyle habits, increased consumption of alcohol and smoking, and growth in the geriatric population are on the rise. origin of the incidence of cardiac disorders. According to estimates by the World Health Organization, cardiovascular diseases account for the largest share of 32% or 17.9 million deaths per year. According to estimates from the Centers for Disease Control and Prevention, about 695,000 deaths in the United States are due to underlying heart disease. Coronary heart disease is recorded in the majority of deaths related to heart disorders. According to estimates from the Centers for Disease Control and Prevention, coronary heart disease caused 360,900 deaths in the United States in 2019.

Another key driving force supporting the growth is the increasing prevalence of hernias such as inguinal hernia, umbilical hernia, congenital diaphragmatic hernia, ventral hernia and others. Some of the risk factors associated with hernias are weight lifting, abdominal surgery, ascites, constipation, and chronic cough which increase pressure on the intra-abdominal regions leading to abdominal hernias.

Inguinal hernias are the most common abdominal hernias and the incidence rate of inguinal hernia repairs in the UK is 10 per 100,000 people and in the US 28 per 100,000 people. Congenital diaphragmatic hernia is due to genetic factors and residual defects of the embryological canal. The aforementioned factors are driving the demand for patches in therapeutic procedures and wound care management.

Highlights of the Cardiovascular and Soft Tissue Repair Patches Market Report

• The soft tissue repair segment dominated the market in 2021 due to the rapid growth in the incidence rate of hernias across the world
• ePTFE segment dominated the market in 2021 due to multiple benefits associated with ePTFE such as high durability, easy availability and high tensile strength
• North America Dominated the market in 2021 due to increasing disease burden, improving healthcare infrastructure, increasing disposable income and rising trend of minimally invasive surgeries

Main topics covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Cardiovascular and Soft Tissue Repair Patches Market Variables, Trends and Scope
3.1 Cardiovascular and Soft Tissue Repair Patches Lineage Market Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/auxiliary market outlook
3.2 Mapping of penetration and growth prospects
3.3 Price Analysis
3.4 Analysis from the users’ point of view
3.4.1 Analysis of consumer behavior
3.4.2 Market Influencer Analysis
3.5 Analysis/breakdown of procedural costs
3.6 List of key end users
3.7 Technology Overview
3.7.1 Technology Calendar
3.8 Regulatory framework
3.8.1 Reimbursement Framework
3.8.2 Standards and compliances
3.9 Cardiovascular and Soft Tissue Repair Patches Market Dynamics
3.9.1 Market Driver Analysis
3.9.2 Market Restraint Analysis
3.9.3 Industry Challenges
3.10 Cardiovascular and Soft Tissue Repair Patches Market Analysis Tools

Chapter 4 Cardiovascular and Soft Tissue Repair Patches Market – Competitive Analysis
4.1 Recent Developments and Impact Analysis, by Major Market Players
4.2 Business Categorization/Competition
4.3 Vendor Landscape
4.3.1 List of Major Distributors and Channel Partners
4.4 Public enterprises
4.4.1 Company Market Position Analysis
4.4.2 Company Ranking, by Region
4.5 Private companies
4.5.1 List of Top Emerging Companies/Technology Disruptors/Innovators
4.5.2 Map of the regional network
4.5.3 Company Market Position Analysis

Chapter 5 Cardiovascular and Soft Tissue Repair Patches Market: Application Estimates and Trend Analysis
5.1 Definition and scope
5.2 Application Market Share Analysis, 2021 & 2030
5.3 Segment Dashboard
5.4 Global Cardiovascular and Soft Tissue Repair Patches Market Revenue Estimates and Forecasts, by Application, 2014- 2030 (USD Million)

Chapter 6 Cardiovascular and Soft Tissue Repair Patches Market: Raw Material Estimates and Trend Analysis
6.1 Definition and scope
6.2 Commodity Market Share Analysis, 2021 & 2030
6.3 Segment Dashboard
6.4 Global Cardiovascular and Soft Tissue Repair Patches Market Revenue Estimates and Forecasts, by Raw Material, 2016- 2030 (USD Million)
6.4.1 ePTFE
6.4.1.1 ePTFE-based Patches Market Revenue Estimates and Forecasts, 2016- 2030 (USD Million)
6.4.2 Biomaterials and tissue-engineered materials
6.4.2.1 Biomaterials and Tissue Engineered Materials Patches Market Revenue Estimates and Forecasts, 2016 – 2030 (USD Million)
6.4.3 Other raw materials
6.4.3.1 Other Raw Material-Based Patches Market Revenue Estimates and Forecasts, 2016 – 2030 (USD Million)

Chapter 7 Cardiovascular and Soft Tissue Repair Patches Market: Regional Estimates and Trend Analysis, by Application and Raw Materials

Chapter 8 Competitive Landscape
8.1 Company Profiles
8.1.1 Baxter
8.1.1.1 Presentation of the company
8.1.1.2 Financial performance
8.1.1.3 Product Benchmarking
8.1.1.4 Strategic initiatives
8.1.2 Admedus
8.1.2.1 Presentation of the company
8.1.2.2 Financial performance
8.1.2.3 Product Benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Abbott (St Jude Medical)
8.1.3.1 Company Overview
8.1.3.2 Financial performance
8.1.3.3 Product Benchmarking
8.1.3.4 Strategic initiatives
8.1.4 LeMaitre Vascular Inc.
8.1.4.1 Presentation of the company
8.1.4.2 Financial performance
8.1.4.3 Product Benchmarking
8.1.4.4 Strategic initiatives
8.1.5 Edwards Life Sciences Society
8.1.5.1 Presentation of the company
8.1.5.2 Financial performance
8.1.5.3 Product Benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Glycar SA Pty Ltd.
8.1.6.1 Presentation of the company
8.1.6.2 Financial performance
8.1.6.3 Product Benchmarking
8.1.6.4 Strategic initiatives
8.1.7 LabCor
8.1.7.1 Presentation of the company
8.1.7.2 Financial performance
8.1.7.3 Product Benchmarking
8.1.7.4 Strategic initiatives
8.1.8 Cryolife, Inc.
8.1.8.1 Presentation of the company
8.1.8.2 Financial performance
8.1.8.3 Product Benchmarking
8.1.8.4 Strategic initiatives
8.1.9 CorMatrix
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product Benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Terumo Medical Society
8.1.10.1 Company Overview
8.1.10.2 Financial performance
8.1.10.3 Product Benchmarking
8.1.10.4 Strategic initiatives
8.1.11 Bard Peripheral Vascular Inc.
8.1.11.1 Presentation of the company
8.1.11.2 Financial performance
8.1.11.3 Product Benchmarking
8.1.11.4 Strategic initiatives
8.1.12 Neovasc
8.1.12.1 Presentation of the company
8.1.12.2 Financial performance
8.1.12.3 Product Benchmarking
8.1.12.4 Strategic initiatives
8.1.13 WL Gore & Associates, Inc.
8.1.13.1 Presentation of the company
8.1.13.2 Financial performance
8.1.13.3 Product Benchmarking
8.1.13.4 Strategic initiatives
8.1.14B.Braun
8.1.14.1 Company overview
8.1.14.2 Financial performance
8.1.14.3 Product Benchmarking
8.1.14.4 Strategic initiatives
8.1.15 Novomedics
8.1.15.1 Company Overview
8.1.15.2 Financial performance
8.1.15.3 Product Benchmarking
8.1.15.4 Strategic initiatives
8.1.16 TEI Biosciences Inc.
8.1.16.1 Company overview
8.1.16.2 Financial performance
8.1.16.3 Product Benchmarking
8.1.16.4 Strategic initiatives
8.1.17 Medical Perugia
8.1.17.1 Presentation of the company
8.1.17.2 Financial performance
8.1.17.3 Product Benchmarking
8.1.17.4 Strategic initiatives
8.1.18 Gunze Limited
8.1.18.1 Presentation of the company
8.1.18.2 Financial performance
8.1.18.3 Product Benchmarking
8.1.18.4 Strategic initiatives
8.1.19 atriummed
8.1.19.1 Presentation of the company
8.1.19.2 Financial performance
8.1.19.3 Product Benchmarking
8.1.19.4 Strategic initiatives
8.1.20 Maverick Biosciences
8.1.20.1 Company Overview
8.1.20.2 Financial performance
8.1.20.3 Product Benchmarking
8.1.20.4 Strategic initiatives
8.1.21 Southern Lights Biomaterials
8.1.21.1 Company overview
8.1.21.2 Financial performance
8.1.21.3 Product Benchmarking
8.1.21.4 Strategic initiatives
8.2 List of other companies

For more information about this report visit https://www.researchandmarkets.com/r/1p8l0y

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets